Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Open Forum Infectious Diseases
|
July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
Stefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Veterinary Medicine and Science
|
May 23, 2023
Causes of thrombocytopenia in dogs in the United Kingdom: A retrospective study of 762 cases
Marina Martín-Ambrosio Francés, Mayank Seth, Mellora Sharman, et al.
Open Forum Infectious Diseases
|
January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study
Ruolan Wang, Mark Underwood, Josep M Llibre, et al.
AIDS (London, England)
|
January 26, 2026
Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutation
Graeme Moyle, Lambert Assoumou, Nathalie De Castro, et al.
AIDS Research and Therapy
|
March 22, 2024
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Sharon Walmsley, Don E Smith, Miguel Górgolas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
AIDS and Behavior
|
September 3, 2024
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
Princy Kumar, Amanda E Clarke, Celia Jonsson-Oldenbüttel, et al.
The Lancet. HIV
|
February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Graeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
Open Forum Infectious Diseases
|
November 30, 2023
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis
Madhusudan Kabra, Tristan J Barber, Clotilde Allavena, et al.
HIV Medicine
|
January 7, 2026
Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 study
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Open Forum Infectious Diseases
|
July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
Stefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Veterinary Medicine and Science
|
May 23, 2023
Causes of thrombocytopenia in dogs in the United Kingdom: A retrospective study of 762 cases
Marina Martín-Ambrosio Francés, Mayank Seth, Mellora Sharman, et al.
Open Forum Infectious Diseases
|
January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study
Ruolan Wang, Mark Underwood, Josep M Llibre, et al.
AIDS (London, England)
|
January 26, 2026
Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutation
Graeme Moyle, Lambert Assoumou, Nathalie De Castro, et al.
AIDS Research and Therapy
|
March 22, 2024
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Sharon Walmsley, Don E Smith, Miguel Górgolas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
AIDS and Behavior
|
September 3, 2024
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
Princy Kumar, Amanda E Clarke, Celia Jonsson-Oldenbüttel, et al.
The Lancet. HIV
|
February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Graeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
Open Forum Infectious Diseases
|
November 30, 2023
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis
Madhusudan Kabra, Tristan J Barber, Clotilde Allavena, et al.
HIV Medicine
|
January 7, 2026
Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 study
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, et al.
Page
of 9